



ETHAMBUTOL DIHYDROCHLORIDE TABLETS

(ETHAMBUTOLI DIHYDROCHLORIDI COMPRESSI)

Draft proposal for revision in *The International Pharmacopoeia*

(05 November 2024)

DRAFT FOR COMMENTS

Please submit your comments through the online platform, PleaseReview™ (<https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=301>). If not registered or included in our mailing list, kindly submit your request with your full name, email address and organization/affiliation to jonesi@who.int, nsp@who.int. For any technical queries, please contact **Dr Herbert Schmidt**, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidth@who.int), with a copy to Ms Sinéad Jones (jonesi@who.int, nsp@who.int). Comments should be submitted through the online platform on or by **05 January 2025**. Please note that only comments received by this deadline will be considered for the preparation of this document. Our working documents are sent out electronically and uploaded into PleaseReview™. The working documents are also placed on the WHO Medicines website (<https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/pharmaceuticals/working-documents-public-consultation>) under the “Working documents in public consultation”. If you wish to receive all our draft guidelines during the course of the year, please send your full name, organization/ affiliation, and email address to jonesi@who.int, nsp@who.int and your name will be added to our electronic mailing list and review platform.

© World Health Organization 2024

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated, or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Ms Sinéad Jones, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: jonesi@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/24.960:

ETHAMBUTOL DIHYDROCHLORIDE TABLETS

(ETHAMBUTOLI DIHYDROCHLORIDI COMPRESSI)

Description	Date
Drafting of the text.	August 2024
Presentation at the 58 th meeting of the Expert Committee on Specifications for Pharmaceutical Preparations	October 2024
Draft monograph sent out for public consultation	November 2024 – January 2025
Further follow-up action as required	

ETHAMBUTOL DIHYDROCHLORIDE TABLETS
(ETHAMBUTOLI DIHYDROCHLORIDI COMPRESSI)

Category. Antibacterial (antituberculosis).

Storage. Ethambutol hydrochloride tablets should be kept in a tightly closed container.

Additional information. Strengths in the current WHO Model list of essential medicines: 100 mg (dihydrochloride). Strengths in the current WHO Model list of essential medicines for children: 100 mg (dihydrochloride).

Requirements

Comply with the monograph for *Tablets*.

Definition. Ethambutol dihydrochloride tablets contain Ethambutol dihydrochloride. They contain not less than 90.0% and not more than 110.0% of the amount of Ethambutol dihydrochloride ($C_{10}H_{24}N_2O_2 \cdot 2HCl$) stated on the label.

Identity tests

- Either tests A, or tests B and C, may be applied.
- A. Carry out the test as described under 1.7 Spectrophotometry in the infrared region. To a quantity of the powdered tablets, nominally containing 0.1 g of Ethambutol dihydrochloride, add 10 mL of methanol R and shake. Filter and evaporate the filtrate to dryness. The infrared absorption spectrum of the residue is concordant with the spectrum obtained from ethambutol dihydrochloride RS or with the *reference spectrum* of ethambutol dihydrochloride.

B. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to ethambutol in the chromatogram obtained with solution (2).

C. Carry out the test as described under 1.14.1 Chromatography, Thin layer chromatography, using the conditions given under “Impurity A”.

Apply separately to the plate 5 µL of each of the following two solutions in methanol R. For solution (A), transfer a quantity of the powdered tablets, nominally containing 20 mg of Ethambutol dihydrochloride, to a 10 mL volumetric flask, add 8 mL of methanol R, sonicate for 5 minutes, and dilute to volume. Filter the solution and use the filtrate. For solution (B), use a solution containing 2 mg of ethambutol dihydrochloride RS per mL. After removing the plate from the chromatographic chamber, allow it to dry in air or in a current of air.

Spray the plate with anisaldehyde/methanol TS and heat it to 105 °C for 10 minutes. Allow the plate to cool and examine the chromatogram in daylight.

The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to ethambutol in the chromatogram obtained with solution (B).

Impurity A. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography, using silica gel R5 as the coating substance and a mixture of 10 volumes of ammonia (~260 g/L) TS, 15 volumes of water R and 75 volumes of methanol R as the mobile phase.

Apply separately to the plate 2 µL of each of the following 3 solutions: For solution (A), transfer a quantity of the powdered tablets, nominally containing 500.0 mg of

Ethambutol dihydrochloride, to a 100 mL flask, add 10.0 mL of methanol R and shake for 5 minutes. Filter the suspension and use the filtrate. For solution (B), dissolve 50.0 mg of 2-aminobutanol R (impurity A) in 100.0 mL of methanol. For solution (C), prepare a solution containing 5 mg of ethambutol dihydrochloride RS and 0.5 mg of 2-aminobutanol R per mL.

Develop the plate for 2/3 of its height. After removing the plate from the chromatographic chamber, allow it to dry in air, heat it at 110 °C for 10 minutes, and allow it to cool. Spray the plate with ninhydrin/ethanol (1 g/ 60 mL) TS, heat it at 110 °C for 5 minutes, and examine the chromatogram in daylight. The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

Any spot due to impurity A in the chromatogram obtained with solution (A) is not more intense than the spot in the chromatogram obtained with solution (B) (1.0%).

Impurity B and C. Prepare the solutions immediately before use. Carry out the test as described under *1.14.1 Chromatography*, High-performance liquid chromatography, using a stainless-steel column (10 cm x 4.6 mm) packed with end-capped particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (3 µm)¹.

Use the following conditions for gradient elution:

Mobile phase A: 50 volumes of methanol for chromatography R and 50 volumes of water R.

Mobile phase B: methanol for chromatography R.

Time (minutes)	Mobile phase A (% V/V)	Mobile phase B (% V/V)	Comments
-------------------	---------------------------	---------------------------	----------

¹ A Luna C18(2) column has been found suitable.

0–30	71	29	Isocratic
30–35	71 to 0	29 to 100	Linear gradient
35–37	0	100	Isocratic
37–38	0 to 71	100 to 29	Return to initial composition
38–48	71	29	Re-equilibration

113 Operate with a flow rate of 1.0 mL per minute. Maintain the column temperature at
114 40 °C. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 215
115 nm.

116 Prepare the following solutions: For solution (1), transfer a quantity of the powdered
117 tablets, nominally containing 200.0 mg of Ethambutol dihydrochloride, to a 20 mL
118 volumetric flask, add about 14 mL of water R, sonicate for about 15 minutes, and
119 dilute with water R to volume, mix and filter. Dilute 2.0 mL of the filtrate to 20.0 mL
120 with acetonitrile R. Transfer 4.0 mL of this solution to a test tube, add 100 µL of
121 triethylamine R and 15 µL of (*R*)-(+)- α -methylbenzyl isocyanate R, insert a stopper,
122 mix, and heat at 70 °C for 20 minutes.

123 For solution (2), dilute 2.0 mL of solution (1) to 200.0 mL with acetonitrile.

124 For solution (3), transfer 4 mg of ethambutol for system suitability RS (containing
125 ethambutol and impurity B) to a test tube, add 4 mL of mixture containing 9 volumes
126 of acetonitrile R and 1 volume of water and 100 µL of triethylamine. Sonicate for 5
127 minutes to dissolve, add 15 µL of (*R*)-(+)- α -methylbenzyl isocyanate R, insert a
128 stopper, mix, and heat at 70 °C for 20 minutes.

129 Inject 10 µL each of solutions (1), (2) and (3) and record the chromatograms.

130 Use the chromatogram obtained with solution (3) to identify the peaks due to the
131 impurity B. The impurities are eluted, if present, at the following relative retention

with reference to ethambutol (retention time about 14 minutes): impurity C about 0.9 and impurity B about 1.3.

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peak due to ethambutol and impurity B is at least 4.0.

In the chromatogram obtained with solution (1):

- the area of any peak corresponding to impurity B is not greater than the area of the peak due to ethambutol in the chromatogram obtained with solution (2) (1.0%);
- the area of any impurity peak with a relative retention of 0.75 to 1.5 with reference to ethambutol is not greater than 0.1 times the area of the peak due to ethambutol in the chromatogram obtained with solution (2) (0.10%).
- The sum of the areas of any peak corresponding to impurity B and of all other impurity peaks with a relative retention of 0.75 to 1.5 with reference to ethambutol is not greater than the area of the peak due to ethambutol in the chromatogram obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.1 times the area of the peak due to ethambutol in the chromatogram obtained with solution (2) (0.1%).

Dissolution. Carry out the test as described under 5.5 Dissolution test for oral dosage forms, using as the dissolution medium, 900 mL of dissolution buffer, pH 6.8, TS and rotating the paddle at 50 revolutions per minute. At 30 minutes, withdraw a sample of 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature and use it as solution (1). For solution (2), dissolve 56.0 mg of ethambutol dihydrochloride RS in the dissolution buffer.

Analyze solutions (1) and (2) as described under 1.14.1 Chromatography, High-performance liquid chromatography, using the chromatographic conditions as described under “Assay”.

For each of the six tablets tested, calculate the total amount of ethambutol dihydrochloride ($C_{10}H_{24}N_2O_2$, 2HCl) in the medium from the results obtained.

Evaluate the results as described under *5.5 Dissolution test for oral dosage forms*, Acceptance criteria. The amount of ethambutol dihydrochloride released is not less than 75% (Q) of the amount declared on the label.

Assay. Carry out the test as under *1.14.1 Chromatography*, High-performance liquid chromatography, using as the stationary phase a stainless steel column packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups (5 μ m).

As the mobile phase, use a solution prepared as follows: transfer 50 g of ammonium acetate R and 0.2 g of copper (II) acetate R to a 1000 mL volumetric flask, add 800 mL water R, shake to dissolve, adjust to pH 5.0 with glacial acetic acid R and dilute to volume with water R. Mix 800 mL of this solution with 200 mL of methanol R.

As the diluent, use a solution prepared as follows: transfer 7.7 g of ammonium acetate R to a 1000 mL volumetric flask, add 800 mL water R, shake to dissolve, adjust to pH 2.0 with phosphoric acid (~1440 g/L) TS and fill up to volume with water R.

Prepare the following solutions in diluent. For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powder, nominally containing 100.0 mg of Ethambutol dihydrochloride, to a 500 mL volumetric flask. Add 400 mL and shake for about 15 minutes to dissolve. Dilute to volume, mix, and filter. For solution (2), dissolve 50.0 mg of ethambutol dihydrochloride RS in 250.0 mL.

Operate with a flow rate of 1.0 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of about 270 nm. Maintain the column temperature at 35 °C.

Inject 20 μ l each of solutions (1) and (2) and record the chromatogram for 15 minutes.

Measure the areas of the peaks corresponding to ethambutol obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of ethambutol dihydrochloride ($C_{10}H_{24}N_2O_2 \cdot 2HCl$) in the tablets using the declared content of $C_{10}H_{24}N_2O_2 \cdot 2HCl$ in ethambutol dihydrochloride RS.

Impurities

The impurities limited by the requirements of this monograph include those listed in the monograph on Ethambutol dihydrochloride.

Reference substance required

Ethambutol dihydrochloride ICRS

Already established ICRS. Intended uses to be adapted.

Ethambutol for system suitability RS (containing ethambutol and the impurity B)

It is intended to refer to the corresponding reference substances established for the European Pharmacopeia.

Reagent to be added

(R)-(+)- α -methylbenzyl isocyanate R

C_9H_9NO .

Content. minimum 99.0%.

Description. A colourless liquid.

Relative density. d_{20}^{20} is about 1.045.

204 *Refractive index.* n_D^{20} is about 1.513.

205 *Boiling point.* 55 °C to 56°C at 2.5 mm Hg.

206 *Enantiomeric purity.* minimum 99.5.

207 *Storage.* At a temperature of 2 °C to 8 °C.

208 **Ninhydrin/ethanol (1 g/ 60 mL) TS**

209 Dissolve 1.0 g of ninhydrin R in 50 mL of dehydrated ethanol R and add 10 mL of
210 glacial acetic acid R.

211 ***